Aplagon

Description

Aplagon develops a therapeutic called APAC, a vascular-injury targeting molecule that combines antiplatelet, anticoagulant, and anti-inflammatory actions to treat thromboinflammatory diseases such as vascular occlusion–related cardiovascular conditions.

Aplagon is located in the Helsinki ecosystem.

Related

• Breye TherapeuticsBreye Therapeutics develops orally administered ophthalmology drugs, including danegaptide and P2X7 receptor antagonists, to treat retinal…
• deCODE geneticsdeCODE genetics operates a human gene-discovery engine that analyzes population-scale genomic data to identify genetic risk factors and…
• Herantis PharmaHerantis Pharma develops disease-modifying therapies designed to stop or reverse progression of neurodegenerative diseases, applying drug…
• Vivasure MedicalVivasure Medical develops PerQseal Elite, a 100% bio-absorbable, sutureless patch-based vascular closure system that seals large-bore…
• Agomab TherapeuticsAgomab Therapeutics develops disease-modifying therapies for fibro-inflammatory conditions through TGFβ/ALK5 (TGFβR1) pathway targeting,…
• Enterprise TherapeuticsEnterprise Therapeutics researches and develops respiratory disease therapies, including inhaled ENaC blocker ETD001, to address mucus…
• NexstimNexstim develops a navigated transcranial magnetic stimulation system that uses sophisticated 3D navigation to provide accurate,…
• Nanoform Finland OyjNanoform Finland Oyj builds nanotechnology-enabled formulation and GMP manufacturing processes to improve bioavailability and drug loading…
• RobeautéRobeauté develops a brain microrobotic platform for neuro-interventions, using rice-sized microrobots and related infrastructure to better…